|
|
|
|
Antibody-Oligo Conjugates (AOCs) and radionuclide-drug conjugates (RDCs) rely on very different components, design strategies, and development paths. To move these modalities forward, science, strategy, and structure need to align.
|
|
|
|
|
Explore the fundamental science behind AOCs, including oligonucleotide synthesis, bioconjugation strategies, and the formulation challenges that arise from oligos’ inherent instability and charge properties.
|
|
|
|
|
Gain valuable insights from industry experts on overcoming the unique chemical, technical, and regulatory challenges of AOC development by watching this recorded webinar.
|
|
|
|
|
Learn how advanced site-specific conjugation technologies are improving the outcomes of the next generation of ADCs, AOCs, and RDCs with enhanced stability, homogeneous DAR, and streamlined development.
|
|
|
|
|
In a recent case study with Sartorius, we demonstrated how our expertise in chromatography helped efficiently remove impurities that arose during production and expedited the conjugation of an oligo-mAb program.
|
|
|
|
|
Even though AEX chromatography can typically be time-consuming and decrease yields, our process maintains high overall yields (over 70%) and fast processing times. This allows for the complete manufacturing of AOCs in just four days.
|
|
|
